Tasly: PD-L1/VEGF Bispecific Antibody's Solid Tumor Indication Phase IIa and Colorectal Cancer Indication Phase IIb Trials Currently Enrolling Patients

Deep News01-05

According to a response on the investor interaction platform on January 5th, Tasly Pharmaceutical Group Co.,Ltd. stated that, as per the company's "2025 Semi-Annual Report," patient enrollment is currently underway for the Phase IIa clinical trial of the PD-L1/VEGF bispecific antibody for solid tumor indications and the Phase IIb trial for colorectal cancer indications.

Furthermore, the clinical trial for the Recombinant Human Fibroblast Growth Factor 21 Injection has advanced to the Ib phase.

Subsequent research and development progress will be announced by the company in accordance with the relevant information disclosure regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162243825?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 22:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162243825","market":"us","top_or_hot":-1,"title":"Tasly: PD-L1/VEGF Bispecific Antibody's Solid Tumor Indication Phase IIa and Colorectal Cancer Indication Phase IIb Trials Currently Enrolling Patients","media":"Deep News","content":"<p>According to a response on the investor interaction platform on January 5th, Tasly Pharmaceutical Group Co.,Ltd. stated that, as per the company's \"2025 Semi-Annual Report,\" patient enrollment is currently underway for the Phase IIa clinical trial of the PD-L1/VEGF bispecific antibody for solid tumor indications and the Phase IIb trial for colorectal cancer indications.</p>\n<p>Furthermore, the clinical trial for the Recombinant Human Fibroblast Growth Factor 21 Injection has advanced to the Ib phase.</p>\n<p>Subsequent research and development progress will be announced by the company in accordance with the relevant information disclosure regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tasly: PD-L1/VEGF Bispecific Antibody's Solid Tumor Indication Phase IIa and Colorectal Cancer Indication Phase IIb Trials Currently Enrolling Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTasly: PD-L1/VEGF Bispecific Antibody's Solid Tumor Indication Phase IIa and Colorectal Cancer Indication Phase IIb Trials Currently Enrolling Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-05 22:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to a response on the investor interaction platform on January 5th, Tasly Pharmaceutical Group Co.,Ltd. stated that, as per the company's \"2025 Semi-Annual Report,\" patient enrollment is currently underway for the Phase IIa clinical trial of the PD-L1/VEGF bispecific antibody for solid tumor indications and the Phase IIb trial for colorectal cancer indications.</p>\n<p>Furthermore, the clinical trial for the Recombinant Human Fibroblast Growth Factor 21 Injection has advanced to the Ib phase.</p>\n<p>Subsequent research and development progress will be announced by the company in accordance with the relevant information disclosure regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1162243825","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162243825","pubTimestamp":1767622319,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"According to a response on the investor interaction platform on January 5th, Tasly Pharmaceutical Group Co.,Ltd. stated that, as per the company's \"2025 Semi-Annual Report,\" patient enrollment is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600535":"天士力","BK0239":"医药制造","BK0183":"MSCI概念","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK0188":"融资融券","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK0012":"证金概念","BK4023":"应用软件","BK0196":"行业龙头","PD":"PagerDuty, Inc.","BK0028":"国家队"},"translate_title":"天士力：PD-L1/VEGF双特异性抗体实体瘤适应症IIa期和结直肠癌适应症IIb期试验目前正在入组患者","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600535":1,"PD":1},"content_text":"According to a response on the investor interaction platform on January 5th, Tasly Pharmaceutical Group Co.,Ltd. stated that, as per the company's \"2025 Semi-Annual Report,\" patient enrollment is currently underway for the Phase IIa clinical trial of the PD-L1/VEGF bispecific antibody for solid tumor indications and the Phase IIb trial for colorectal cancer indications.\nFurthermore, the clinical trial for the Recombinant Human Fibroblast Growth Factor 21 Injection has advanced to the Ib phase.\nSubsequent research and development progress will be announced by the company in accordance with the relevant information disclosure regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162243825","isCrawlerRequest":true}